Evidence map›Paper›PMID 38004546›Full record

ArticlePharmaceutics2023

Characterization and Pharmacokinetic Assessment of a New Berberine Formulation with Enhanced Absorption In Vitro and in Human Volunteers.

Julia Solnier, Yiming Zhang, Yun Chai Kuo, Min Du, Kyle Roh, Roland Gahler, Simon Wood, Chuck Chang

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Molecular landscape of Berberine's therapeutic potential in gastrointestinal disorders.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Julia SolnierISURA, Burnaby, BC V3N 4S9, Canada.ORCID 0000-0003-2784-1435
Yiming ZhangISURA, Burnaby, BC V3N 4S9, Canada.
Yun Chai KuoISURA, Burnaby, BC V3N 4S9, Canada.
Min DuISURA, Burnaby, BC V3N 4S9, Canada.ORCID 0000-0001-8118-2683
Kyle RohISURA, Burnaby, BC V3N 4S9, Canada.
Roland GahlerFactors Group R & D, Burnaby, BC V3N 4S9, Canada.
Simon WoodSchool of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA 6845, Australia.
Chuck ChangISURA, Burnaby, BC V3N 4S9, Canada.ORCID 0009-0004-8843-0650
Institute of Indigenous Peoples' Health · CAUniversity of British Columbia · CA

Funding

Factors Group of Nutritional Companies
6 · The paper itself

Abstract

Berberine is a plant-origin quaternary isoquinoline alkaloid with a vast array of biological activities, including antioxidant and blood-glucose- and blood-lipid-lowering effects. However, its therapeutic potential is largely limited by its poor oral bioavailability. The aim of this study was to investigate the in vitro solubility and Caco-2 cell permeability followed by pharmacokinetic profiling in healthy volunteers of a new food-grade berberine delivery system (i.e., Berberine LipoMicel

Indexed as

berberinebioavailabilityCaco-2 cell permeabilityfood-grade delivery systemLipoMicelpharmacokineticssolubility

Identifiers

PMID38004546
PMCPMC10675484
OpenAlexW4388139883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.